$1.44
+0.04(2.50%)
Mkt Cap $160M
$0.82
$1.54
52-Week Range
At a Glance
AI-generatedThis SEC Form 40-F filing serves as the Annual Report for Cardiol Therapeutics Inc.
6-K
Cardiol Therapeutics announced its year-end 2025 operational update, highlighting accelerated enrollment in the pivotal Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis, positive Phase II ARCHER results in acute myocarditis, advancement of the CRD-38 program toward Phase I, U.S. patent protection extension, board strengthening, and a strengthened cash runway into Q4 2027.$160M
Market Cap
—
Revenue
-$62M
Net Income
Employees18
Fundamentals
How The Business Makes Money
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Industry Drug Manufacturers - Specialty & Generic
Activity
What Changed Recently
Company Profile
CIK0001702123
ISINCA14161Y2006
CUSIP14161Y200
Phone289 910 0850
Address2265 Upper Middle Road East, Oakville, ON, L6H 0G5, CA
SEC EDGAR